Active Biotech AB (ST:ACTI) — Market Cap & Net Worth
Market Cap & Net Worth: Active Biotech AB (ACTI)
Active Biotech AB (ST:ACTI) has a market capitalization of $17.19 Million (Skr159.75 Million) as of May 4, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #25489 globally and #528 in its home market, demonstrating a -11.01% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Active Biotech AB's stock price Skr0.06 by its total outstanding shares 2636067170 (2.64 Billion). Analyse cash flow conversion of Active Biotech AB to see how efficiently the company converts income to cash.
Active Biotech AB Market Cap History: 2015 to 2026
Active Biotech AB's market capitalization history from 2015 to 2026. Data shows change from $2.33 Billion to $17.19 Million (-35.30% CAGR).
Active Biotech AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Active Biotech AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
55.30x
Active Biotech AB's market cap is 55.30 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $2.33 Billion | $16.27 Million | -$193.53 Million | 143.28x | N/A |
| 2016 | $1.80 Billion | $19.04 Million | -$59.58 Million | 94.31x | N/A |
| 2017 | $299.03 Million | $20.25 Million | -$108.79 Million | 14.77x | N/A |
| 2018 | $687.02 Million | $20.05 Million | -$36.88 Million | 34.26x | N/A |
| 2019 | $514.40 Million | $8.43 Million | -$36.07 Million | 61.06x | N/A |
| 2020 | $514.71 Million | $6.72 Million | -$32.12 Million | 76.54x | N/A |
| 2021 | $344.22 Million | $6.22 Million | -$49.88 Million | 55.30x | N/A |
Competitor Companies of ACTI by Market Capitalization
Companies near Active Biotech AB in the global market cap rankings as of May 4, 2026.
Key companies related to Active Biotech AB by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Active Biotech AB Historical Marketcap From 2015 to 2026
Between 2015 and today, Active Biotech AB's market cap moved from $2.33 Billion to $ 17.19 Million, with a yearly change of -35.30%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr17.19 Million | +31.74% |
| 2025 | Skr13.05 Million | -57.72% |
| 2024 | Skr30.86 Million | -76.17% |
| 2023 | Skr129.50 Million | -52.55% |
| 2022 | Skr272.90 Million | -20.72% |
| 2021 | Skr344.22 Million | -33.12% |
| 2020 | Skr514.71 Million | +0.06% |
| 2019 | Skr514.40 Million | -25.13% |
| 2018 | Skr687.02 Million | +129.75% |
| 2017 | Skr299.03 Million | -83.35% |
| 2016 | Skr1.80 Billion | -22.98% |
| 2015 | Skr2.33 Billion | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Active Biotech AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $17.19 Million USD |
| MoneyControl | $17.19 Million USD |
| MarketWatch | $17.19 Million USD |
| marketcap.company | $17.19 Million USD |
| Reuters | $17.19 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Active Biotech AB
Active Biotech AB (publ), a biotechnology company, engages in the research, development, and production of pharmaceutical products in Sweden. It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase Ib/IIa clinical trial to treat relapsed refractory multiple myeloma; Laquinimod, a mechanism which is in phase 1 for the treatment of severe inflammatory eye diseases, such as… Read more